| Previous Close | 116.94 |
| Open | 116.66 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 116.37 - 116.77 |
| 52 Week Range | 102.07 - 121.24 |
| Volume | 1,053,730 |
| Avg. Volume | 2,157,588 |
| Net Assets | 36.76B |
| NAV | 116.40 |
| PE Ratio (TTM) | -60.78 |
| Yield | 2.14% |
| YTD Return | 4.46% |
| Beta (3y) | 0.98 |
| Expense Ratio (net) | 0.20% |
| Inception Date | 2000-05-22 |
- Market Realist•4 days ago
How ProQuad/MMR-II/Varivax Vaccines Are Expected to Perform in 2017
In 2016, Merck’s (MRK) ProQuad reported revenues of ~$495 million, which reflected 9% year-over-year growth.
- Market Realist•5 days ago
Merck’s Diabetes Franchise Could Generate Steady Revenues in 2017
In 2016, Merck’s Janumet (sitagliptin and metformin HCl) reported revenues of around $2.2 billion, which reflected ~2% YoY growth.
- Market Realist•21 days ago
Abbott’s Nutrition Segment: Chinese Headwinds Continue
Abbott Laboratories (ABT) reported about $1.6 billion of revenues from its Nutrition segment, representing a YoY (year-over-year) fall of ~1.0%.
